Abstract
Peroxisome Proliferator-Activated Receptors (PPARs) are ligand-activated transcription factors that govern lipid and glucose homeostasis playing a central role in cardiovascular disease, obesity, and diabetes. These receptors show a high degree of stereoselectivity towards several classes of drugs. This review provides an overview of most papers reporting the influence of stereochemistry on PPAR activation. Some cases in which chirality is a crucial point in determining the PPAR binding mode are reviewed and discussed with the aim to show how enantiomeric recognition originates at the molecular level. The structural characterization by crystallographic methods of complexes formed by PPARs with their ligands turns out to be an essential tool to explain receptor stereoselectivity.
Keywords: Chirality, stereoselectivity, peroxisome proliferator-activated receptors, crystallographic methods, selective modulators, nuclear receptors, thiazolidinediones, fibrates, transcription factors, cardiovascular disease, obesity, diabetes, tereoselectivity, PPAR activation, complexes
Current Topics in Medicinal Chemistry
Title: Structural Insight Into the Crucial Role of Ligand Chirality in the Activation of PPARs by Crystallographic Methods
Volume: 11 Issue: 7
Author(s): F. Loiodice and G. Pochetti
Affiliation:
Keywords: Chirality, stereoselectivity, peroxisome proliferator-activated receptors, crystallographic methods, selective modulators, nuclear receptors, thiazolidinediones, fibrates, transcription factors, cardiovascular disease, obesity, diabetes, tereoselectivity, PPAR activation, complexes
Abstract: Peroxisome Proliferator-Activated Receptors (PPARs) are ligand-activated transcription factors that govern lipid and glucose homeostasis playing a central role in cardiovascular disease, obesity, and diabetes. These receptors show a high degree of stereoselectivity towards several classes of drugs. This review provides an overview of most papers reporting the influence of stereochemistry on PPAR activation. Some cases in which chirality is a crucial point in determining the PPAR binding mode are reviewed and discussed with the aim to show how enantiomeric recognition originates at the molecular level. The structural characterization by crystallographic methods of complexes formed by PPARs with their ligands turns out to be an essential tool to explain receptor stereoselectivity.
Export Options
About this article
Cite this article as:
Loiodice F. and Pochetti G., Structural Insight Into the Crucial Role of Ligand Chirality in the Activation of PPARs by Crystallographic Methods, Current Topics in Medicinal Chemistry 2011; 11 (7) . https://dx.doi.org/10.2174/156802611795165106
DOI https://dx.doi.org/10.2174/156802611795165106 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fibroblast Growth Factor: Promising Target for Schizophrenia
Current Drug Targets Tissue Doppler Imaging: Beautiful Noise
Current Cardiology Reviews Diabetes Mellitus Induced Impairment of Male Reproductive Functions: A Review
Current Diabetes Reviews A Perspective on Clinical Islet Transplantation: Past, Present and Developments for Future
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Biological Signatures of Alzheimer’s Disease
Current Topics in Medicinal Chemistry Postprandial Hypotension - Novel Insights into Pathophysiology and Therapeutic Implications
Current Vascular Pharmacology Psychosocial Risk Factors Related to Ischemic Heart Disease in Women
Current Pharmaceutical Design An Update in Incretin-Based Therapy: A Focus on Dipeptidyl Peptidase - 4 Inhibitors
Current Diabetes Reviews Selective Glucocorticoid Receptor Ligands
Medicinal Chemistry Transcription Factors in Autoimmune Diseases
Current Pharmaceutical Design T Cell Proliferative Responses and IgG Antibodies to β2GPI in Patients with Diabetes and Atherosclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Correlation between Serum 25 hydroxy vitamin D level and plasminogen activator inhibitor 1 in type 2 diabetic patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeted Renal Delivery of Protein Kinase Inhibitors for the Treatment of Chronic Kidney Disease
Current Signal Transduction Therapy Burkholderia mallei and Burkholderia pseudomallei: The Causative Micro-organisms of Glanders and Melioidosis
Recent Patents on Anti-Infective Drug Discovery An insight into the Interaction between Clopidogrel and Proton Pump Inhibitors
Current Drug Metabolism Redefining the Role of Long-Acting Phosphodiesterase Inhibitor Tadalafil in the Treatment of Diabetic Erectile Dysfunction
Current Diabetes Reviews IL-1β and IL-1Ra Variant Profiles in Turkish Patients with Diabetic Peripheral Neuropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Acute Cystitis Caused by Commensal Neisseria oralis: A Case Report and Review of the Literature
Infectious Disorders - Drug Targets Coffee to Reduce Risk of Type 2 Diabetes? : A Systematic Review
Current Diabetes Reviews Analysis of the Potential Association of Drug-Metabolizing Enzymes <i>CYP2C9*3</i> and <i>CYP2C19*3</i> Gene Variations With Type 2 Diabetes: A Case-Control Study
Current Drug Metabolism